GW Pharmaceuticals Plc (GWPH)

151.81
7.90 5.50
NASDAQ : Health Technology
Prev Close 143.95
Open 145.18
Day Low/High 145.18 / 152.48
52 Wk Low/High 90.14 / 179.65
Volume 492.81K
Avg Volume 445.70K
Exchange NASDAQ
Shares Outstanding 30.45M
Market Cap 4.44B
EPS -10.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
8 Things That Could Lift Biotech Stocks Out of Bear Market

8 Things That Could Lift Biotech Stocks Out of Bear Market

Biotech stocks are buried in a deep hole. To climb out, companies will have to generate some positive news.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Securities Fraud By GW Pharmaceuticals Plc And Certain Officers And Directors

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Securities Fraud By GW Pharmaceuticals Plc And Certain Officers And Directors

Levi & Korsinsky, LLP announces that it has commenced an investigation of GW Pharmaceuticals plc ("GW Pharmaceuticals" or "the Company") (NASDAQ:GWPH) concerning possible violations of federal securities laws by the...

Jim Cramer Says Own Salesforce.com, Regeneron, First Solar

Jim Cramer Says Own Salesforce.com, Regeneron, First Solar

TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer says Macy's should benefit from the cold weather and energy stocks are still 'too dangerous' to put money into.

This Is the Only Stock to Buy Right Now to Profit From Legalized Weed

This Is the Only Stock to Buy Right Now to Profit From Legalized Weed

Legalized cannabis is now the fastest-growing industry in the U.S. We highlight a "green rush" stock that analysts say will soar 124% next year.

'Mad Money' Lightning Round: It's OK to Buy Pandora Media Now

'Mad Money' Lightning Round: It's OK to Buy Pandora Media Now

Cramer is sticking with Bristol-Myers, is avoiding Marathon Oil and is a believer in Cypress Semiconductor.

Jim Cramer's 'Mad Money' Recap: Winners, Losers and the Chasm Between Them

Jim Cramer's 'Mad Money' Recap: Winners, Losers and the Chasm Between Them

There are haves and have-nots in every industry this year, Cramer says.

'Mad Money' Lightning Round: Take Mattel Over Hasbro

'Mad Money' Lightning Round: Take Mattel Over Hasbro

Cramer calls Raytheon one of the best military plays and GW Pharmaceuticals one of the most speculative stocks.

Jim Cramer's 'Mad Money' Recap: Play the Hand You're Dealt

Jim Cramer's 'Mad Money' Recap: Play the Hand You're Dealt

While some investors are throwing back all their cards and giving up, the skilled players are keeping what works and augmenting their hands with what'll keep working, Cramer says.

Jim Cramer Answers 8 Questions From Viewers Including CEO Henry Blodget

Jim Cramer Answers 8 Questions From Viewers Including CEO Henry Blodget

From the floor of the NSYE on Wednesday, Jim Cramer answered viewers' questions on the stock market, including questions on Tesla, Chipotle, Ford, PayPal, Under Armour and Lockheed Martin.

Jim Cramer Fields Questions From Viewers Including Henry Blodget

Jim Cramer Fields Questions From Viewers Including Henry Blodget

TheStreet's Jim Cramer tackled viewer questions on the economy from the NYSE Wednesday. His first viewer question was from Henry Blodget, an investor and CEO of Business Insider.

GW Pharmaceuticals Announces Date And Time Change For Q4 And Year-End 2015 Financial Results And Conference Call

GW Pharmaceuticals Announces Date And Time Change For Q4 And Year-End 2015 Financial Results And Conference Call

-Change to After Market on 7 December to Facilitate Inclusion of Additional Epidiolex Data-

'Mad Money' Lightning Round: Northrop Grumman, Lockheed Martin Both Terrific

'Mad Money' Lightning Round: Northrop Grumman, Lockheed Martin Both Terrific

Cramer likes Johnson & Johnson, Stryker and Edwards Lifesciences, while avoiding all Chinese stocks.

Jim Cramer's 'Mad Money' Recap: Winners Remain When Rates Rise

Jim Cramer's 'Mad Money' Recap: Winners Remain When Rates Rise

When interest rates begin to rise, it may be harder to find winners, Cramer said. But only a pessimist would stop looking.

'Mad Money' Lightning Round: Buy AT&T, Verizon, Walgreens Boots Alliance

'Mad Money' Lightning Round: Buy AT&T, Verizon, Walgreens Boots Alliance

Cramer says you have to be willing to take some pain on Radius Health and GW Pharmaceuticals.

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan

It's government shutdown season and that's never good for the stock market, Cramer says. So he'll be watching Washington as well as earnings from Johnson & Johnson and Wells Fargo.

'Mad Money' Lightning Round: Buy, Buy, Buy Blackstone and KKR

'Mad Money' Lightning Round: Buy, Buy, Buy Blackstone and KKR

Cramer favors Costco over Wal-Mart and sees GW Pharmaceuticals as a long-term holding.

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan

Cramer will be watching a plethora of economic data and earnings from Vail Resorts, Paychex and General Electric, among others.

Biotech Stock Mailbag: Bristol, Exelixis, Lion Bio, GW Pharma

Biotech Stock Mailbag: Bristol, Exelixis, Lion Bio, GW Pharma

Biotech columnist Adam Feuerstein answers readers' questions about health care.

Cramer: I'm Impressed by GW Pharma's Cannabis Data, Wait to Buy Kimberly-Clark

Cramer: I'm Impressed by GW Pharma's Cannabis Data, Wait to Buy Kimberly-Clark

GW Pharma's drug showed impressive results for treating schizophrenia, Cramer says. Investors looking to buy high-quality consumer companies like Kimberly-Clark should wait for the Fed's rate decision.

Jim Cramer: Rite Aid and GW Pharmaceuticals Are Ripe for a Rally

Jim Cramer: Rite Aid and GW Pharmaceuticals Are Ripe for a Rally

Rite Aid and GW Pharmaceuticals both have positive catalysts — and bullish analyst coverage — to help push their share prices higher, Cramer says.

TheStreet Quant Rating: D (Sell)